Alrizomadlin(APG-115, AA-115) is a highly potent and efficacious inhibitor of MDM2 and binds to MDM2 with IC50 of 3.8 nM. It exhibits potent antiproliferative and apoptogenic activities and also significantly reduces tumor burden and prolonged survival in AML xenograft models.
More Information Supplier PageLuvixasertib (CFI-402257) is an inhibitor of threonine tyrosine kinase (TTK) with IC50 of 1.7 nM and Ki of 0.1 nM, respectively. It is a potential therapeutic for treating hepatocellular carcinoma that works directly by inhibiting cell-cycle checkpoints in cancer cells and indirectly by mobilizing immune cells from the tumor microenvironment.
More Information Supplier PageLuvixasertib (CFI-402257) is an inhibitor of threonine tyrosine kinase (TTK) with IC50 of 1.7 nM and Ki of 0.1 nM, respectively. It is a potential therapeutic for treating hepatocellular carcinoma that works directly by inhibiting cell-cycle checkpoints in cancer cells and indirectly by mobilizing immune cells from the tumor microenvironment.
More Information Supplier PageRapaLink-1, a third-generation bivalent inhibitor of mTOR, combines Rapamycin with MLN0128 using an inert chemical linker. It demonstrates efficacy against resistant mutants of malignant brain tumors and inhibits cancer cell progression by binding to mesenchymal markers.
More Information Supplier PageLuvixasertib (CFI-402257) is an inhibitor of threonine tyrosine kinase (TTK) with IC50 of 1.7 nM and Ki of 0.1 nM, respectively. It is a potential therapeutic for treating hepatocellular carcinoma that works directly by inhibiting cell-cycle checkpoints in cancer cells and indirectly by mobilizing immune cells from the tumor microenvironment.
More Information Supplier PageLuvixasertib (CFI-402257) is an inhibitor of threonine tyrosine kinase (TTK) with IC50 of 1.7 nM and Ki of 0.1 nM, respectively. It is a potential therapeutic for treating hepatocellular carcinoma that works directly by inhibiting cell-cycle checkpoints in cancer cells and indirectly by mobilizing immune cells from the tumor microenvironment.
More Information Supplier PageINT-777 (S-EMCA) is a potent and selective agonist of TGR5(GPCR19) with EC50 of 0.18 μM, 3.9 μM and 1.45 μM for TGR5, TGR5(N76A) and TGR5(Y89F) respectively.
More Information Supplier PagePhalloidin is a mushroom-derived toxin which can be used to label F-actin of the cytoskeleton with fluorochrome .
More Information Supplier PageMavoglurant (AFQ056) is a structurally selective, non-competitive antagonist of mGlu5 receptor with an IC50 of 30 nM. It exhibits efficacy in treatment of L-dopa induced dyskinesia in Parkinson’s disease and Fragile X syndrome.
More Information Supplier PagePlicamycin (Mithramycin A) a selective inhibitor of Sp1, is a natural polycyclic aromatic polyketide isolated from Streptomyces strains. It binds to GC-rich DNA sequences, displacing Sp1 transcription factor from oncogene promoters, inhibiting their expression, with anti-tumor and neuroprotective effects.
More Information Supplier Page
